Reuters -- France's Sanofi-Aventis took a knife to its pipeline, slashing 14 drugs from development including four in final trials, and posted a better-than-expected rise in quarterly net income, boosting shares.
Reuters -- France's Sanofi-Aventis took a knife to its pipeline, slashing 14 drugs from development including four in final trials, and posted a better-than-expected rise in quarterly net income, boosting shares.
